BioTime, Inc. today announced that it has received approval from The Spanish Agency of Medicines and Medical Devices to begin human clinical trials of Reneviaa , a unique biomaterial used as a delivery matrix for autologous adipose derived cells to treat the loss of subcutaneous adipose tissue arising from trauma, surgical resection, and congenital ... (more)
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130828005365&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130828005365&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment